Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Abuse Potential Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential Study of PF-00345439

NCT01986283
View directory record Official record
Conditions
Opioid Users
Interventions
Capsule, PF-00345439, oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers

NCT05023096
View directory record Official record
Conditions
Electronic Nicotine Delivery System Flavors
Interventions
Tobacco product administration and assessment
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

NCT00158236
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine, Buprenorphine and Naloxone, Hydromorphone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Medication-based Analgesia in Humans

NCT02901275
View directory record Official record
Conditions
Pain, Cannabis, Opioid Use, Unspecified
Interventions
Within-subject test of blinded study medications
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Results available

Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study

NCT02563769
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Addiction, Cocaine Abuse, Cocaine-Related Disorders
Interventions
Clavulanic acid, Intravenous cocaine, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Abuse Potential of Cebranopadol in Humans

NCT05256108
View directory record Official record
Conditions
Human Abuse Potential
Interventions
Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users

NCT07404306
View directory record Official record
Conditions
General Anesthesia
Interventions
HSK3486, propofol, Placebo
Drug
Lead sponsor
Haisco-USA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Carisbamate as a Potential Treatment for Alcohol Dependence

NCT02435381
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Abuse, Substance Abuse
Interventions
Carisbamate, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

NCT07813026
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 1

NCT05868213
View directory record Official record
Conditions
Cannabis, Memory, Electroencephalography
Interventions
Cannabis (smoked flower)
Drug
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

NCT05988710
View directory record Official record
Conditions
Analgesia, Abuse Opioids, Pain
Interventions
Buccal Buprenorphine 300 mcg, Buccal Buprenorphine 600 mcg, Buccal Buprenorphine 900 mcg, Buccal Placebo, Oral Placebo, Oral immediate-release oxycodone 10mg, Buccal Buprenorphine 450mcg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users

NCT03509285
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Alprazolam Placebo, Cenobamate placebo, Alprazolam, Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Lorcaserin, Placebo, Cocaine Infusion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

NCT04331288
View directory record Official record
Conditions
Potential Treatment for Alcohol Dependence-Alcohol Interaction
Interventions
PT150, Beverage
Drug · Other
Lead sponsor
Pop Test Oncology LLC
Industry
Eligibility
21 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

NCT03389750
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Intravenous Challenge Drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
View directory record Official record
Conditions
Drug Abuse
Interventions
Istradefylline, Phentermine 45 mg, Placebo
Drug · Other
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience

NCT04570436
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 1800 mg, diazepam 20 mg, placebo
Drug · Other
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

NCT03657355
View directory record Official record
Conditions
Healthy Recreational Drug Users
Interventions
ACT-541468, Suvorexant, Zolpidem, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users

NCT02218021
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Samidorphan, Placebo, Oxycodone
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

NCT01759446
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

NCT05319756
View directory record Official record
Conditions
Abuse Potential
Interventions
gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
Drug
Lead sponsor
Viatris Specialty LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 22, 2026, 4:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)

NCT05567354
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 22, 2026, 4:36 PM EDT